Clinical COPD phenotypes: a novel approach using principal component and cluster analyses
暂无分享,去创建一个
D. Caillaud | N. Roche | I. Tillie‐Leblond | I. Court-Fortune | P. Burgel | J. Paillasseur | P. Chanez | R. Escamilla | T. Perez | P. Carré | Pierre-Régis Burgel | -. IsabelleTillie | Leblond | Philippe Carré | P. Carré
[1] P. Jones,et al. The St George's Respiratory Questionnaire. , 1991, Respiratory medicine.
[2] D. Nagel,et al. Cluster analysis in diagnosis. , 1992, Clinical chemistry.
[3] P. Jones,et al. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. , 1992, The American review of respiratory disease.
[4] P. O'Byrne,et al. Is nedocromil sodium effective treatment for asthma? , 1993, The European respiratory journal.
[5] J. Muir,et al. Pulmonary rehabilitation in chronic respiratory insufficiency , 1993 .
[6] J E Cotes,et al. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. , 1993, The European respiratory journal. Supplement.
[7] J E Cotes,et al. Lung volumes and forced ventilatory flows , 1993, European Respiratory Journal.
[8] R. Deyo,et al. Pulmonary rehabilitation in chronic respiratory insufficiency. 7. Health-related quality of life among patients with chronic obstructive pulmonary disease. , 1994, Thorax.
[9] T. Seemungal,et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. , 1998, American journal of respiratory and critical care medicine.
[10] D. Postma,et al. Chronic obstructive pulmonary disease. , 2002, Clinical evidence.
[11] I. Guyon,et al. Detecting stable clusters using principal component analysis. , 2003, Methods in molecular biology.
[12] Ciro Casanova,et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. , 2004, The New England journal of medicine.
[13] I. Pavord,et al. Multi‐dimensional phenotyping: towards a new taxonomy for airway disease , 2005, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[14] B. Celli,et al. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. , 2005, American journal of respiratory and critical care medicine.
[15] R. Mitchell. Chronic Obstructive Pulmonary Disease Phenotypes and Their Clinical Relevance , 2006 .
[16] B. Nordestgaard,et al. Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen City Heart Study. , 2006, American journal of respiratory and critical care medicine.
[17] B. Celli. Chronic obstructive pulmonary disease phenotypes and their clinical relevance , 2006 .
[18] B. Celli. Roger s. Mitchell lecture. Chronic obstructive pulmonary disease phenotypes and their clinical relevance. , 2006, Proceedings of the American Thoracic Society.
[19] A. Khodursky,et al. Functional Genomics: Methods And Protocols , 2007 .
[20] T. Ng,et al. Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. , 2007, Archives of internal medicine.
[21] David M Kent,et al. Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification. , 2007, JAMA.
[22] Bartolome Celli,et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.
[23] Robert A Wise,et al. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee , 2007, Thorax.
[24] Mike Thomas,et al. Cluster analysis and clinical asthma phenotypes. , 2008, American journal of respiratory and critical care medicine.
[25] M. Decramer,et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. , 2008, The New England journal of medicine.
[26] G. Turino. COPD and biomarkers: the search goes on , 2008, Thorax.
[27] D. Mannino,et al. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD , 2008, European Respiratory Journal.
[28] S. Zakynthinos,et al. Chest wall volume regulation during exercise in COPD patients with GOLD stages II to IV , 2008, European Respiratory Journal.
[29] B. Celli,et al. Predictors of Survival in COPD: more than just the FEV1. , 2008, Respiratory medicine.
[30] G. Criner,et al. National Emphysema Treatment Trial: the major outcomes of lung volume reduction surgery in severe emphysema. , 2008, Proceedings of the American Thoracic Society.
[31] H. Magnussen,et al. Extrapulmonary effects of chronic obstructive pulmonary disease on physical activity: a cross-sectional study. , 2008, American journal of respiratory and critical care medicine.
[32] M. Weatherall,et al. Distinct clinical phenotypes of airways disease defined by cluster analysis , 2009, European Respiratory Journal.
[33] Nicolas Roche,et al. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. , 2009, Chest.
[34] D. Donaire-Gonzalez,et al. Physical activity and clinical and functional status in COPD. , 2009, Chest.